TAO Synergies (TAOX) Asset Utilization Ratio (2026)
TAO Synergies' (TAOX) quarterly Asset Utilization Ratio came in at 0.03 in Q2 2026, up 22.5% quarter-over-quarter from 0.02 in Q1 2026.
Powered by 
Analysis
TAO Synergies (TAOX) Asset Utilization Ratio (2026) Analysis & Trends
TAO Synergies (TAOX) has reported Asset Utilization Ratio for 1 consecutive years, with 0.03 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Asset Utilization Ratio changed N/A year-over-year to 0.03; the trailing twelve-month figure through Jun 2026 stood at 0.03 (changed N/A YoY), and the FY2025 full-year result was 0.01, changed N/A from the prior year.
- Asset Utilization Ratio grew to 0.03 in Q2 2026 per TAOX's latest filing, from 0.02 in the prior quarter.
- Across five years, Asset Utilization Ratio topped out at 0.03 in Q2 2026 and bottomed at 0.02 in Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.51 Bn | 197.52 Bn | 7.24 Bn | 0.40 |
| 2 | Gilead Sciences | 181.48 Bn | 178.30 Bn | 6.22 Bn | 0.58 |
| 3 | Vertex Pharmaceuticals | 132.45 Bn | 124.60 Bn | 2.84 Bn | 0.47 |
| 4 | Regeneron Pharmaceuticals | 82.87 Bn | 74.88 Bn | 3.93 Bn | 0.38 |
| 5 | Argenx Se | 61.59 Bn | 56.41 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.72 Bn | 49.59 Bn | 52.00 Mn | 0.20 |
| 7 | Alnylam Pharmaceuticals | 34.13 Bn | 30.82 Bn | 992.69 Mn | 0.90 |
| 8 | Biogen | 31.29 Bn | 30.01 Bn | 1.96 Bn | 0.33 |
| 9 | Roivant Sciences | 30.31 Bn | 30.31 Bn | 1.16 Mn | 0.00 |
| 10 | TAO Synergies | 30.90 Mn | 30.90 Mn | - | 0.03 |